Top Companies in the Cardiometabolic Disease Market

The cardiometabolic disease market was valued at USD 34.1 billion in 2023. The market is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, with the values likely to reach USD 54.8 billion by 2032. The market growth is driven by the prevalence of conditions like obesity, diabetes, and cardiovascular diseases across the 8 major markets.

Cardiometabolic disorders such as obesity, diabetes, high blood pressure, and heart diseases have common risk factors such as unhealthy diet and genetics. Managing cardiometabolic disease includes making lifestyle adjustments, taking medications, and considering surgical procedures like bariatric surgery. Oral medications are used to address high blood pressure and type 2 diabetes, with injectables offering more precise management of diabetes. The method of delivering medication is determined by the patient's condition and how well the treatment works.

The market is influenced by the rise in cardiometabolic disorders, spurred by alterations in lifestyle that lead to obesity, type 2 diabetes, and cardiovascular disorders. Older people have an increased likelihood of needing medical care, which puts more strain on healthcare systems. Progress in treatment, such as new medications and customized combination therapies, is enhancing patient outcomes. Further, recent data reveals that around 11% of adults in the United States  have been diagnosed with diabetes, while about 10% have been diagnosed with cardiovascular disease, leading to an increased need for advanced treatment options, which in turn results in greater healthcare costs and improvements in the market.

In March  2024, the U.S. Food and Drug Administration authorized the use of the Wegovy injection to lower cardiovascular risks in adults suffering from obesity or cardiovascular disease. It is advised to incorporate the medication with a calorie-restricted diet and physical activity to achieve optimal outcomes. The rise in such innovative drug approvals by the regulatory bodies is expected to support market expansion in the coming years. Additionally, the growth in strategic partnerships is a major market trend. For instance, in March  2024, UMass Memorial Health partnered with Google Cloud to enhance cardiometabolic care through artificial intelligence, machine learning, and data analytics, with the goal of transforming healthcare delivery for patients affected by cardiometabolic diseases.

Let’s explore the profile of top companies leading the cardiometabolic disease market in 2024.

Eli Lilly and Company

Eli Lilly and Company is a pharmaceutical company that creates and sells healthcare products for diverse medical ailments. In July  2023, they announced an agreement to acquire Versanis Bio, a biopharmaceutical company focusing on cardiometabolic diseases. Further, in June  2024, Lilly's tirzepatide was demonstrated to decrease the intensity of obstructive sleep apnea, possibly averting severe cardiometabolic issues.

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals focuses on developing RNA interference therapies for genetic disorders. In April  2024, the positive outcomes of a Phase 2 study on zilebesiran for uncontrolled high blood pressure were disclosed. The research seeks to reduce blood pressure and enhance heart health, demonstrating encouraging progress in treating hypertension among patients with cardiometabolic problems.

Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, situated in California, specializes in the development of RNA interference drugs. The company intends to advance plozasiran in the CAPITAN Phase 3 study for cardiovascular outcomes by June  2024. This study focuses on individuals with mixed hyperlipidemia and persistent risk of atherosclerotic cardiovascular disease, further exploring cardiometabolic conditions such as familial chylomicronemia syndrome and severe hypertriglyceridemia.

Novartis AG

Novartis AG is a pharmaceutical company based in Basel, Switzerland. In July  2023, the FDA granted permission for the company to broaden the utilization of Leqvio® (inclisiran) for adults at high risk of heart disease with elevated LDL-C levels. This injectable medication will now be used on more adults with cardiometabolic disorders, highlighting the significance of reducing cardiovascular risk factors prior to heart-related incidents.

Novo Nordisk A/S

The Danish pharmaceutical company, Novo Nordisk A/S, is dedicated to finding and creating biological drugs for diabetes, haemophilia, growth hormone disorders, rare blood and endocrine diseases, and obesity. In September  2023, they collaborated with the Broad Institute of MIT and Harvard to conduct research on diabetes and cardiometabolic diseases in the United States. The partnership's goal is to discover drug targets for different subtypes of type 2 diabetes and the genetic factors behind cardiac fibrosis.

Boehringer Ingelheim International GmbH

Boehringer Ingelheim International GmbH, a branch of CH Boehringer Sohn AG & Co KG, specializes in creating, manufacturing, and marketing drugs, parasiticides, vaccines, and therapeutics for medical needs that have not been addressed. In July  2024, they announced progress in their pipeline, focusing on cardiovascular, renal, and metabolic health, with the initiation of five new clinical studies targeting cardiometabolic conditions.

Merck & Co., Inc.

Merck & Co., Inc. is a pharmaceutical company headquartered in New Jersey. Merck's primary focus is on the development and marketing of prescription drugs, biologic treatments, vaccines, and products for animal health. Their products focus on a range of health issues, including heart problems, cancer, immune system issues, infectious diseases, and diabetes.